...
首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >PLAGL2-EGFR-HIF-1/2 alpha Signaling Loop Promotes HCC Progression and Erlotinib Insensitivity
【24h】

PLAGL2-EGFR-HIF-1/2 alpha Signaling Loop Promotes HCC Progression and Erlotinib Insensitivity

机译:PLAGL2-EGFR-HIF-1/2 alpha信号环促进HCC进展和ERLOTINIB不敏感性

获取原文
获取原文并翻译 | 示例
           

摘要

Background and Aims Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide, hence a major public health threat. Pleomorphic adenoma gene like-2 (PLAGL2) has been reported to play a role in tumorigenesis. However, its precise function in HCC remains poorly understood.
机译:背景与目的肝细胞癌(HCC)是全球第三大癌症相关死亡原因,因此是一个重大的公共卫生威胁。据报道,多形性腺瘤基因样-2(PLAGL2)在肿瘤发生中起作用。然而,其在肝癌中的确切作用仍不清楚。

著录项

  • 来源
  • 作者单位

    China Pharmaceut Univ Ctr New Drug Safety Evaluat &

    Res State Key Lab Nat Med Nanjing 210017;

    China Pharmaceut Univ Ctr New Drug Safety Evaluat &

    Res State Key Lab Nat Med Nanjing 210017;

    China Pharmaceut Univ Ctr New Drug Safety Evaluat &

    Res State Key Lab Nat Med Nanjing 210017;

    China Pharmaceut Univ Ctr New Drug Safety Evaluat &

    Res State Key Lab Nat Med Nanjing 210017;

    China Pharmaceut Univ Ctr New Drug Safety Evaluat &

    Res State Key Lab Nat Med Nanjing 210017;

    China Pharmaceut Univ Ctr New Drug Safety Evaluat &

    Res State Key Lab Nat Med Nanjing 210017;

    China Pharmaceut Univ Ctr New Drug Safety Evaluat &

    Res State Key Lab Nat Med Nanjing 210017;

    China Pharmaceut Univ Ctr New Drug Safety Evaluat &

    Res State Key Lab Nat Med Nanjing 210017;

    China Pharmaceut Univ Ctr New Drug Safety Evaluat &

    Res State Key Lab Nat Med Nanjing 210017;

    China Pharmaceut Univ Ctr New Drug Safety Evaluat &

    Res State Key Lab Nat Med Nanjing 210017;

    China Pharmaceut Univ Ctr New Drug Safety Evaluat &

    Res State Key Lab Nat Med Nanjing 210017;

    China Pharmaceut Univ Ctr New Drug Safety Evaluat &

    Res State Key Lab Nat Med Nanjing 210017;

    China Pharmaceut Univ Ctr New Drug Safety Evaluat &

    Res State Key Lab Nat Med Nanjing 210017;

    China Pharmaceut Univ Ctr New Drug Safety Evaluat &

    Res State Key Lab Nat Med Nanjing 210017;

    China Pharmaceut Univ Ctr New Drug Safety Evaluat &

    Res State Key Lab Nat Med Nanjing 210017;

    Nanjing Med Univ Jiangsu Inst Canc Res Jiangsu Canc Hosp Dept Chemotherapy 42 Baizi Ting;

    Nanjing Med Univ Jiangsu Inst Canc Res Jiangsu Canc Hosp Dept Chemotherapy 42 Baizi Ting;

    Catholic Univ Argentina Inst Biomed Res Buenos Aires DF Argentina;

    Nanjing Med Univ Jiangsu Inst Canc Res Jiangsu Canc Hosp Dept Chemotherapy 42 Baizi Ting;

    Nanjing Univ Affiliated Drum Tower Hosp Dept Gen Surg Med Sch Nanjing Peoples R China;

    China Pharmaceut Univ Ctr New Drug Safety Evaluat &

    Res State Key Lab Nat Med Nanjing 210017;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 消化系及腹部疾病;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号